8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): 

February 15, 2022

Johnson & Johnson

 (Exact name of registrant as specified in its charter)

New Jersey	1-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 

(Address of Principal Executive Offices)

 (Zip Code) 

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐             Recommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

               CFR 240.14d-2(b)) 

☐             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $1.00	JNJ	New York Stock Exchange
0.650% Notes Due May 2024	JNJ24C	New York Stock Exchange
5.50% Notes Due November 2024	JNJ24BP	New York Stock Exchange
1.150% Notes Due November 2028	JNJ28	New York Stock Exchange
1.650% Notes Due May 2035	JNJ35	New York Stock Exchange

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Johnson & Johnson (the “Company”) announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately. Mr. Adamczyk will serve as a member of the Board’s Audit Committee and Compensation & Benefits Committee, effective as of April 28, 2022. As a non-employee Director of the Company, Mr. Adamczyk will receive compensation as described in the “Director Compensation” section of the Company's 2022 Proxy Statement.

The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.

Item 9.01            Financial Statements and Exhibits

(d)     Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press Release dated February 15, 2022
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Johnson & Johnson
			(Registrant)
Date:	February 15, 2022	By:	/s/ Matthew Orlando
			Matthew Orlando Corporate Secretary

EX-99.1

Press Contacts: Kim Montagnino (631) 375-8779 kmontag@its.jnj.com Investor Contacts: Jessica Moore (732) 524-2955 jmoore29@its.jnj.com Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors New Brunswick, NJ (February 15, 2022) – Johnson & Johnson announced today that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors. “I am delighted to welcome Darius to Johnson & Johnson’s Board of Directors,” said Alex Gorsky, Executive Chairman, Johnson & Johnson. “Darius is an accomplished global leader with decades of experience and a track record of growing businesses. He is also a champion of sustainability and investments in innovation to improve the lives of people around the world. Darius’s extensive knowledge of numerous business sectors will add important dimension and a unique perspective to the Johnson & Johnson Board of Directors. I am incredibly proud of the background, diversity and caliber of all our Board members and on behalf of the Board, we look forward to working with Darius as the Company continues to deliver transformational innovation, create healthier communities, and put better health within reach of more people around the world.” About Darius Adamczyk Darius Adamczyk is a visionary who brings decades of global business leadership experience and operational and regulatory expertise. Currently, Mr. Adamczyk is the Chairman and CEO of Honeywell. In this role, he has helped to bring solutions and technology to market that help to make the world safer, more productive and more sustainable, and built a culture of excellence. Before stepping into the CEO role, Mr. Adamczyk served as President and Chief

2 Operating Officer. Prior to this, Mr. Adamczyk served in multiple leadership roles across Honeywell’s business segments. Mr. Adamczyk joined Honeywell in 2008 when Metrologic, a manufacturer of laser and scanning technology, where he was Chief Executive Officer, was acquired. Mr. Adamczyk has also previously held leadership positions with Ingersoll Rand and Booz Allen Hamilton, and he began his career as an electrical engineer at General Electric. Mr. Adamczyk currently serves as the Vice Chair of the U.S.-China Business Council, as a member of the Business Roundtable Board of Directors and as a member of the Business Council and Aspen Economic Strategy Group. Mr. Adamczyk holds an MBA from Harvard University, a master’s degree in computer engineering from Syracuse University and a bachelor’s degree in electrical and computer engineering from Michigan State University. “I am honored to join Johnson & Johnson’s Board of Directors at this important time for both the Company and for the future of healthcare,” said Darius Adamczyk. “Johnson & Johnson is a values-driven organization that is helping people lead better lives and creating healthier communities. I look forward to working with my fellow directors in support of the management team as they continue to create long-term value for all of Johnson & Johnson’s stakeholders.” The full Board of Directors list is available on the Johnson & Johnson website at https://www.jnj.com/leadership/our-leadership-team#board-of-directors. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most

3 broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. ###

XML

Cover	Feb. 15, 2022
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Feb. 15, 2022
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity File Number	1-3215
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000200406
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE